GSK

Financier looks to parlay a $5M Alzheimer’s deal into instant $172.5M IPO

Vivek Ramaswamy
Just before Christmas last year, a newly formed Bermuda-based biotech run by former hedge fund partner Vivek Ramaswamy struck a deal to in-license a shelved Alzheimer’s drug from GlaxoSmithKline ($GSK) with plans to put it into Phase III. That late-stage study won’t start until the fourth quarter, but the newborn biotech isn’t waiting around at the starting line. The […]

Is This How We’ll Cure Cancer?

moreView todays social media effects on GSKView the latest stocks trending across Twitter. Click to view dashboardSee who GlaxoSmithKline is hiring next, click here to view […]

FDA Approves New Omega-3 Supplement

moreView todays social media effects on GSKView the latest stocks trending across Twitter. Click to view dashboardSee who GlaxoSmithKline is hiring next, click here to view […]

GSK, Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards

[PR Newswire] – RESEARCH TRIANGLE PARK, N.C., May 6, 2014 /PRNewswire/ — GlaxoSmithKline (@GSKUS) and Triangle Community Foundation (@TriComFdn) today issued the call for applications for the GSK IMPACT Awards. This annual awards program will honor up t moreView todays social media effects on GSKView the latest stocks trending across Twitter. Click to view dashboardSee who GlaxoSmithKline is hiring next, […]